Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Pharmed: Journal of Pharmaceutical Science and Medical Research
Syaiful Prayogi
Program Studi Farmasi Fakultas Sains dan Teknologi Universitas Peradaban
Chemistry Education Health Professions Medicine & Pharmacology Public Health Other

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Profil Tekanan Darah dan Kejadian ESO Pasien Penerima Monoterapi Antihipertensi di Puskesmas Kabupaten Banyumas Aulia Rahman; Luthfi Hidayat Maulana; Syaiful Prayogi
Pharmed: Journal of Pharmaceutical Science and Medical Research Vol 5, No 1 (2022)
Publisher : Universitas PGRI Madiun

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25273/pharmed.v5i1.11998

Abstract

Hypertension is a cardiovascular disease with the highest prevalence. JNC VIII categorizes hypertension if blood pressure > 140/90 mmHg. This study aims to determine the patient's profile, blood pressure, and the possible incidence of ESO in patients receiving antihypertensive monotherapy in Banyumas Regency, the eastern region. The study was conducted retrospectively. Samples were carried out using total sampling. The sample size in this study was 44 patients. The highest number of patients was female, i.e. 82%, with the majority having primary education/equivalent. The monotherapy used was Amlodipine (class CCBs), Candesartan (class ARB), and Lisinopril (class ACEI) with the highest number of prescriptions being Amlodipine (70.5%). The incidence of ESO that is often experienced is dizziness by 6.8%. There was no significant difference in the effectiveness of each monotherapy used with Asymp. Sig = 0.666 (for systolic pressure) and 0.716 (for diastolic pressure). 
Molecular Docking of Bicycloproline Derivative Synthetic Compounds on Envelope Protein: Anti-SARS-CoV-2 Drug Discovery Syaiful Prayogi; Binar Asrining Dhiani; Asmiyenti Djaliasrin Djalil
JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA Vol. 10 No. 1 (2023): JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIA
Publisher : Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jfiki.v10i12023.11-21

Abstract

Background: Although a SARS-CoV-2 vaccine is readily available, new cases of COVID-19 are still occurring. New drug discovery is needed to treat COVID-19. Protein E is one of the potential targets. Two synthetic compounds of bicycloproline derivatives have the potential to be developed. Objective: This study aimed to estimate the interaction of bicycloproline compounds to protein E in-silico. Methods: There were two bicycloproline-derived compounds, MI-09 and MI-30, used in docking. Remdesivir was used as a reference ligand. The crystal structure of the E protein was created using homology modeling, while the test compound was drawn using the Marvin Sketch. MOE 2022.02 and BDS 2021 were used for docking and visualization processes. Results: The pentamer of the SARS-CoV-2 E protein obtained a clash score (1.06); poor rotatomer (0.00%); favored rotamers (98.11%); Ramachandran favored (96.43%); Ramachandran outlier (1.78%); Rama Z-score (-1.08); and mol probity (1.04). Research shows promising inhibition potential of the MI-09 and MI-30. The MI-30 has the best binding energy of -10.3326 kcal/mol. Conclusion: The docking results show that MI-30 has potency as an inhibitor of protein E and can be developed in treating COVID-19. Further research is needed to confirm the result by in vitro and in vivo studies.
Co-Authors Asmiyenti Djaliasrin Djalil Aulia Rahman Binar Asrining Dhiani Luthfi Hidayat Maulana